Ionis Pharma (IONS) Stock Forecast & Price Target
Ionis Pharma (IONS) Analyst Ratings
Bulls say
Ionis Pharmaceuticals is experiencing a positive outlook driven by robust performance in R&D revenue, which amounted to $141 million, surpassing expectations and underpinned by favorable payer dynamics with a high percentage of patients incurring $0 out-of-pocket costs. The company has successfully expanded its portfolio with solid contributions from products such as Wainua, which generated $42 million in sales in the fourth quarter of 2024, resulting in $10 million in royalty revenue for Ionis. Additionally, the firm's optimism regarding its pipeline, including promising Phase III trial results and a strong shift in patient preferences towards its latest offerings, positions Ionis favorably in the growing therapeutic market for rare and chronic diseases.
Bears say
Ionis Pharmaceuticals is projected to continue incurring substantial losses, with no anticipated profitability for several years. The company has revised its revenue guidance for 2025, forecasting a bottom-end revenue of $600 million, which is below the $670 million consensus estimate and reflects a year-over-year decline driven by lower R&D revenue. Additionally, Ionis faces significant risks, including potential market share erosion of Spinraza due to competitive pressures, a failure to translate impressive reductions in lipoprotein(a) to cardiovascular outcomes, and delays in unlocking the full value of their platform beyond liver-targeted therapies.
This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Ionis Pharma (IONS) Analyst Forecast & Price Prediction
Start investing in Ionis Pharma (IONS)
Order type
Buy in
Order amount
Est. shares
0 shares